Aleix Prat, Director of the Clínic Barcelona Comprehensive Cancer Center at Barcelona Clinical Hospital, shared a post on LinkedIn:
“Very happy to share this new work just published in npjBreastCancer Nature Portfolio, led by Gaia Griguolo and Maria Vittoria Dieci and colleagues Università degli Studi di Padova, where we explore the interplay between tumor biology and immune activation in early HR+/HER2- breast cancer.
Using gene expression profiling and immune analyses from two neoadjuvant trials, we show that the subset of HR+/HER2- tumors with a basal-like molecular profile has significantly higher TILs, higher immune gene signatures, and higher expression of PD-1/PD-L1-related pathways.
This challenges the idea that HR+/HER2− breast cancer is uniformly “immunologically cold” and suggests that a biologically aggressive but immunogenic subgroup may be particularly relevant for future chemo-immunotherapy strategies.
Congratulations to the whole team for a very elegant and thoughtful piece of work — and thanks for the great collaboration.”
Title: Basal-like HR + /HER2- breast cancers show higher tumor-infiltrating lymphocytes and immune signatures with potential therapeutic implications
Authors: Gaia Griguolo, Michele Bottosso, Laia Paré, Federica Miglietta, Daniele Giulio Generali, Antonino Musolino, Simon Spazzapan, Grazia Maria Vernaci, Tommaso Giarratano, Rocco Cappellesso, Silvio Bicciato, Federico Piacentini, Enrico Tagliafico, Katia Cagossi, Anna Tosi, Francesca Schiavi, Aleix Prat, Maria Vittoria Dieci, Valentina Guarneri
Read the Full Article.
More posts featuring Aleix Prat on OncoDaily.